Anavex Life Sciences Corp (AVXL)

[powerwalker]

Sent out by the biased Alzheimer's Association today ... guess what it states

This message is sent to all Alzheimer's Association and Alzheimer's Impact Movement board members, all Alzheimer's Association staff, and volunteers and supporters of AIM and the Alzheimer's Association.
This week, researchers gathered in San Francisco to share the latest clinical trial results for treatments in the fight against Alzheimer’s disease. The meeting has featured scientific breakthroughs and developments, many of which have been supported by the Alzheimer’s Association scientific grant program and our own research initiatives. It was an exciting and encouraging week for those in the Alzheimer’s community, as seen in media coverage. Here are the top five things we learned:
• Data from the Phase 3 global clinical trial of lecanemab confirm this treatment changes the course of the disease in a meaningful way for people in the earliest stages of Alzheimer’s disease. The Alzheimer's Association has called for the Food and Drug Administration’s (FDA) accelerated approval of lecanemab and for the Centers for Medicare and Medicaid Services (CMS) to revise its coverage policy with the utmost urgency. Read the full statement from the Alzheimer’s Association here.
• We heard research updates and progress from researchers whose work was accelerated by Alzheimer’s Association strategic research grants, especially programs funded by our Zenith Society and Part the Cloud. This pipeline of potential new treatments offers hope for the Alzheimer’s and dementia community.
• With a new phase of treatment upon us, we need to work together to prepare clinicians and health systems to provide the best care possible in the safest way. The Alzheimer’s Association is leading the way with Alzheimer's Network for Treatment and Diagnostics (ALZ-NET), a multi-site provider network designed to collect safety and efficacy data over a long period of time to see how new FDA-approved treatments and diagnostics improve health outcomes.
• We are encouraged by continuing advancements of biomarkers — blood tests, cerebrospinal fluid (CSF) and brain imaging — which allow clinicians and researchers to identify the right participants for the right clinical trials, as well as potential with early detection, diagnosis and monitoring of Alzheimer’s disease.
• The Alzheimer’s Association believes that the future of Alzheimer’s treatment will be a combination of drugs that target different aspects of the disease and risk reduction interventions. Lifestyle interventions — such as those being studied in the U.S. POINTER study — combined with disease-modifying treatments could be the most promising approach to treat Alzheimer’s disease.
The Alzheimer's Association remains committed to advancing science and acting to ensure that all who may benefit from FDA-approved treatments and future clinical interventions will have access. As always, your support of the Alzheimer’s Association is appreciated as together we move closer toward our vision of a world without Alzheimer’s and all other dementia.

Joanne Pike, DrPH
President